Text Size

Analgesic Treatment Mediated by Arcoxia

This study has been completed.
Sponsor:
Information provided by:
Merck
ClinicalTrials.gov Identifier:
NCT00380523
First received: September 22, 2006
Last updated: NA
Last verified: September 2006
History: No changes posted
  Purpose

Allow physicians to test the efficacy of arcoxia in patients with acute pain.


Condition Intervention Phase
Pain
 Drug: MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days
 Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Analgesic Treatment Mediated by Arcoxia

Further study details as provided by Merck:

Primary Outcome Measures:
  • Evaluate pain using the verbal analog scale (evaluate pain before starting treatment and then evaluate pain every day after had taken arcoxia up to three days)

Secondary Outcome Measures:
  • Patient satisfaction with the drug therapy using PGART scale
  • Patient satisfaction was obtained at the end of treatment(on third day)

Estimated Enrollment: 237
Study Start Date: April 2005
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of acute pain susceptible of pharmacological treatment
  • Greater than 18 years of age
  • Voluntary acceptance to participate in the study and signature of the informed consent form

Exclusion Criteria:

  • Allergy to etoricoxib or any of its components
  • Less than 18 years old
  • Patient is taking anticoagulants
  • Patient that already has taken any drug as analgesic
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00380523

Sponsors and Collaborators
Merck
Investigators
Study Director: Medical Monitor Merck
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00380523     History of Changes
Other Study ID Numbers: 2006_034
Study First Received: September 22, 2006
Last Updated: September 22, 2006
Health Authority: Ecuador: Public Health Ministry

Additional relevant MeSH terms:
Analgesics
Etoricoxib
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
 Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Antirheumatic Agents

ClinicalTrials.gov processed this record on May 23, 2013